Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

University Hospital, Montpellier196 enrolled

Overview

This study is multicentric, single-blind, and interventional with a randomization into two parallel arm, between a standard of care information and an additional information of the patient, with a 12 month follow up. The aim of this study is to evaluate the effectiveness of a personalized information program versus information provided from standard of care in patients taking Xarelto for Stroke Prevention in Atrial Fibrillation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Enrollment

196

Conditions

Non-valvular Atrial Fibrillation

Interventions

XareltoDRUG

Taking conventional charge

Experimental: Personalized information interventionOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients treated with rivaroxaban chronically, (atrial fibrillation non-valvular under current AMM) for less than one year whatever anti vitamin K treatment history * Affiliate or beneficiary of a social security system. * Patient who formulated its "does not oppose" to participate in this research * Age higher than or equal to 18 years Exclusion Criteria: * Opposition to participation * Patient don't understand french language * Patient does not have responsibility for the management of treatment (treatment administered by a nurse at home, or by caregivers) * Tutorship or curatoship * Law-protected patient * Pregnant women or breast-feeding

Locations (1)

Heart and vascular diseases service

Montpellier, France

Outcomes

Primary Outcomes

The occurence of serious adverse event

Time frame: 12 months

Secondary Outcomes

The number ok hospitalization

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.